Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
Idle factories, not the sales force, took the hit
Production costs rose far faster than 1.4% sales growth while selling costs fell, so the margin loss sits in the plants.
For investorsWill the outage prove temporary, or did it cost share?
For foundersBuying options on the future: the stake-first playbook
Interventional Cardiology added more sales than the whole company did, covering declines in Electrophysiology, the earlier growth leader, and Watchman.
Litigation, restructuring and an impairment, absent or credits a year ago, took more operating income than the drop in gross profit.
Devices consumed in each procedure kept a 66.7% gross margin, even in a quarter when plants stood idle.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Boston Scientific from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
